Correlations of CYP2C9∗3/CYP2D6∗10/CYP3A5∗3 gene polymorphisms with efficacy of etanercept treatment for patients with ankylosing spondylitis: A case–control study

BACKGROUND: The tumor necrosis factor alpha (TNF-α) inhibitor etanercept has been proven to be effective in the treatment of ankylosing spondylitis (AS), while genetic polymorphism may affect drug metabolism or drug receptor, resulting in interindividual variability in drug disposition and efficacy....

Descripción completa

Detalles Bibliográficos
Autor principal: Chen, Yuan-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
6900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340430/
https://www.ncbi.nlm.nih.gov/pubmed/28248857
http://dx.doi.org/10.1097/MD.0000000000005993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340430/
https://www.ncbi.nlm.nih.gov/pubmed/28248857
http://dx.doi.org/10.1097/MD.0000000000005993

Ejemplares similares